Bausch + Lomb Acquires Trukera Medical

Bausch + Lomb has completed the acquisition of Trukera Medical, a US-based ophthalmic medical diagnostic company. The financial details of the acquisition were not disclosed.

Trukera Medical's Innovative ScoutPro Device

Trukera Medical, previously owned by private equity firm AccelMed Partners and other shareholders, is known for its innovative ScoutPro device, a portable point-of-care tool designed to precisely measure osmolarity.

Strategic Expansion in Surgical Sector and Dry Eye Management

The acquisition is expected to bolster Bausch + Lomb's footprint in the surgical sector within the United States, while also enhancing its portfolio in the field of dry eye management. ScoutPro plays a crucial role in detecting hyperosmolarity, a condition that slit lamp examinations often fail to identify. This condition is a significant indicator and primary cause of asymptomatic dry eye disease (DED) and ocular surface disease (OSD), which can have adverse effects on outcomes in corneal, cataract, and refractive surgeries if not addressed effectively prior to procedures.

Luc Bonnefoy, President of Surgical at Bausch + Lomb, highlighted the strategic importance of integrating ScoutPro into their offerings: "As a global leader in dry eye disease management, as well as cataract and refractive medical devices and implants, we’re uniquely positioned to optimize pre-surgical preparation to help ensure positive post-surgical outcomes. ScoutPro has already become a valuable preoperative diagnostic tool for many U.S. surgeons, and with our scale we believe it can have an even greater impact."

Adam Szaronos, CEO and President of Trukera Medical, expressed optimism about the acquisition: "By joining a global leader like Bausch + Lomb, we are excited to get this valuable tool in the hands of more surgeons to benefit more patients." He emphasized the potential of ScoutPro to improve outcomes by addressing hyperosmolarity, which is known to affect vision quality and patient satisfaction following cataract surgery.

Legacy and Innovation in Ophthalmic Care

Founded in 2009 as TearLab and rebranded as Trukera Medical in 2022 to reflect its expanded focus on corneal health, the company introduced tear osmolarity testing to eye care and has conducted over 24 million tests globally with its TearLab Osmolarity System.

The acquisition of Trukera Medical underscores Bausch + Lomb's commitment to advancing ophthalmic care through innovative diagnostics and reinforces its leadership in providing comprehensive solutions for eye health.

*Stay in the loop and make sure not to miss real-time breaking news about ophthalmology. Join our community by subscribing to OBN newsletter now, and get weekly updates.